Trial is the first to show a delay in confirmed disability progression in non-relapsing secondary progressive MS
A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, demonstrated a 31% delay ...
Apr 8, 2025
0
34